JP5244593B2 - 免疫原性構築物 - Google Patents

免疫原性構築物 Download PDF

Info

Publication number
JP5244593B2
JP5244593B2 JP2008525615A JP2008525615A JP5244593B2 JP 5244593 B2 JP5244593 B2 JP 5244593B2 JP 2008525615 A JP2008525615 A JP 2008525615A JP 2008525615 A JP2008525615 A JP 2008525615A JP 5244593 B2 JP5244593 B2 JP 5244593B2
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
seq
map
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008525615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504149A5 (https=
JP2009504149A (ja
Inventor
ハーモン−テイラー，ジョン
ブル，ティモシー，ジョン
Original Assignee
ハブ バクシーンズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハブ バクシーンズ リミテッド filed Critical ハブ バクシーンズ リミテッド
Publication of JP2009504149A publication Critical patent/JP2009504149A/ja
Publication of JP2009504149A5 publication Critical patent/JP2009504149A5/ja
Application granted granted Critical
Publication of JP5244593B2 publication Critical patent/JP5244593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008525615A 2005-08-09 2006-08-03 免疫原性構築物 Active JP5244593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70659405P 2005-08-09 2005-08-09
US60/706,594 2005-08-09
PCT/GB2006/002893 WO2007017635A1 (en) 2005-08-09 2006-08-03 Immunogenic constructs

Publications (3)

Publication Number Publication Date
JP2009504149A JP2009504149A (ja) 2009-02-05
JP2009504149A5 JP2009504149A5 (https=) 2009-08-27
JP5244593B2 true JP5244593B2 (ja) 2013-07-24

Family

ID=36992793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525615A Active JP5244593B2 (ja) 2005-08-09 2006-08-03 免疫原性構築物

Country Status (11)

Country Link
US (2) US7892566B2 (https=)
EP (1) EP1913020B1 (https=)
JP (1) JP5244593B2 (https=)
AT (1) ATE466876T1 (https=)
AU (1) AU2006277828B2 (https=)
CA (1) CA2617506C (https=)
DE (1) DE602006014164D1 (https=)
DK (1) DK1913020T3 (https=)
ES (1) ES2345274T3 (https=)
NZ (1) NZ565695A (https=)
WO (1) WO2007017635A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
GB201811382D0 (en) * 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2026041756A1 (en) * 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225324A (en) * 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
FR2682967B1 (fr) 1991-10-25 1994-01-14 Pasteur Institut Nouveau promoteur de m. paratuberculosis. son utilisation pour le clonage et l'expression de sequences nucleotidiques.
AU708456B2 (en) * 1994-12-20 1999-08-05 New Zealand Pastoral Agriculture Research Institute Limited Methods and compositions for detecting and treating mycobacterial infections using an ahpCF operon
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
EP2196473A1 (en) * 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
JP2005514041A (ja) * 2002-01-11 2005-05-19 イーデー−レリースタツト・インステイテユート・フオール・デイールホウデライ・エイ・デイールゲゾントハイト・ベー・ベー ミコバクテリウム・パラツベルクローシス感染の診断薬及びワクチン
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte

Also Published As

Publication number Publication date
WO2007017635A1 (en) 2007-02-15
AU2006277828A1 (en) 2007-02-15
EP1913020B1 (en) 2010-05-05
EP1913020A1 (en) 2008-04-23
NZ565695A (en) 2011-01-28
ES2345274T3 (es) 2010-09-20
US8147850B2 (en) 2012-04-03
US7892566B2 (en) 2011-02-22
DK1913020T3 (da) 2010-08-09
DE602006014164D1 (de) 2010-06-17
US20110129502A1 (en) 2011-06-02
AU2006277828B2 (en) 2012-02-02
CA2617506C (en) 2015-02-03
CA2617506A1 (en) 2007-02-15
JP2009504149A (ja) 2009-02-05
ATE466876T1 (de) 2010-05-15
US20090203593A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
CN102834106A (zh) 产生针对结核病的免疫应答的方法
US8147850B2 (en) Immunogenic constructs
JP7035063B2 (ja) ｐｈｏＰ－ｐｈｏＲを過剰発現する組換えＢＣＧ
US20250152691A1 (en) Immunogenic composition for paratuberculosis
CN106102768A (zh) 分枝杆菌抗原组合物
JP2016513078A (ja) 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
JP2004514451A (ja) マイコバクテリア感染に対する防御
KR101955365B1 (ko) 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신
EP4642479A1 (en) Modified bcg vaccine
WO1997013858A2 (en) Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US20230050225A1 (en) Vaccines targeting Neisseria gonorrhoeae
WO2012025759A2 (en) Method
US20130273093A1 (en) Method for Immunising a Subject against Mycobacterium Tuberculosis or Mycobacterium Bovis
Tascon et al. Protection against tuberculosis by plasmid DNA
Gregory RE Tascon, MJ Colston, E. Stavropoulos, S. Ragno, D. Gregory and DB Lowrie Division of Mycobacterial Research, National Institute for Medical Research, London, UK

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090709

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130408

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160412

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5244593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250